Media headlines about ProPhase Labs (NASDAQ:PRPH) have trended somewhat positive on Tuesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProPhase Labs earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.6402006243951 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, ValuEngine cut ProPhase Labs from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.
ProPhase Labs (PRPH) traded up $0.02 during trading on Tuesday, hitting $2.38. The stock had a trading volume of 1,800 shares, compared to its average volume of 6,133. ProPhase Labs has a twelve month low of $1.78 and a twelve month high of $2.48. The stock has a market capitalization of $28.96, a PE ratio of 3.05 and a beta of 0.15.
ProPhase Labs declared that its board has initiated a stock buyback program on Friday, November 10th that allows the company to repurchase 1,700,000 shares. This repurchase authorization allows the company to buy shares of its stock through a tender offer. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.
In other ProPhase Labs news, CEO Ted William Karkus sold 424,789 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $2.30, for a total value of $977,014.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 29.60% of the company’s stock.
About ProPhase Labs
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.